Checked
Arcus Biosciences, Inc.
NYSE: RCUS · Pharmaceutical Preparations · Hayward, CA
- Revenue
- $247M
- -4.3% vs. prior year
- Net income
- -$353M
- -142.9% net margin
- Total assets
- $1.14B
- Diluted EPS
- -$3.29
Company details
As reported to the SEC
- SEC CIK
- 1724521
- Stock
- NYSE: RCUS
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- Headquarters
- 3928 Point Eden Way, Hayward, CA 94545
- Incorporated in
- Delaware
- Fiscal year end (SEC record)
- December 31
- Filer status
- Large accelerated filer
- Phone
- (510) 694-6200
- Employer ID (EIN)
- 47-3898435
- Last annual report
- 02/25/2026
- Last quarterly report
- 08/05/2026
Annual financials
U.S. dollars, as tagged in each annual report's XBRL data. Later restatements replace earlier numbers. Select a date to open the filing.
| Fiscal year ended | 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 |
|---|---|---|---|---|---|
| Revenue | $247M | $258M | $117M | $112M | $383M |
| Operating income | -$386M | -$330M | -$340M | -$280M | $54M |
| Net income | -$353M | -$283M | -$307M | -$267M | $53M |
| Diluted earnings per share | -$3.29 | -$3.14 | -$4.15 | -$3.71 | $0.71 |
| Research and development | $523M | $448M | $340M | $288M | $257M |
| Total assets | $1.14B | $1.15B | $1.09B | $1.34B | $1.59B |
| Total liabilities | Not reported | Not reported | Not reported | Not reported | $750.4M |
| Shareholders' equity | $631M | $485M | $462M | $657M | $842M |
| Cash and cash equivalents | $222M | $150M | $127M | $206M | $148M |
| Long-term debt | $99M | $48M | $0 | Not reported | Not reported |
| Cash from operations | -$482M | -$170M | -$306M | $438M | -$256M |
| Capital expenditures | $2M | $6M | $24M | $6M | $26M |
Federal and state records filed under the name Arcus Biosciences, Inc.
Matched by the company name and by the subsidiary names it lists in SEC filings and other public records, after removing endings like Inc., Corp. and Holdings. Records marked Subsidiary were filed under a subsidiary name. A subsidiary that is not listed in those records is not included, and an unrelated business with the same name can appear.
Work visa sponsorship
Certified H-1B and PERM green card filings with the Department of Labor
| Employer on filing | H-1B | PERM |
|---|---|---|
| Arcus Biosciences, Inc.Hayward, CA | 8 | 0 |
Recent filings
111 recent filings on record; insider ownership forms (3, 4, 5 and 144) are not listed here
Swipe the table sideways to see more columns.
| Form | Filed | Period |
|---|---|---|
| 8-KOther events | 10/23/2026 | 10/21/2026 |
| 424B5Prospectus supplement | 10/22/2026 | None |
| 424B5Prospectus supplement | 10/21/2026 | None |
| 8-KResults of operations | 10/21/2026 | 10/21/2026 |
| 8-KOther events | 10/20/2026 | 10/20/2026 |
| CT ORDERSEC filing | 09/28/2026 | None |
| 10-QQuarterly report | 08/05/2026 | 06/30/2026 |
| 8-KResults of operations | 08/05/2026 | 08/05/2026 |
| 8-KShareholder vote results | 06/12/2026 | 06/11/2026 |
| 10-QQuarterly report | 05/05/2026 | 03/31/2026 |
| 8-KResults of operations | 05/05/2026 | 05/05/2026 |
| ARSAnnual report to shareholders | 04/21/2026 | 12/31/2025 |
| DEFA14AAdditional proxy materials | 04/21/2026 | None |
| DEF 14AProxy statement | 04/21/2026 | 06/11/2026 |
| 8-KOther events | 04/20/2026 | 04/20/2026 |
| SCHEDULE 13G/AOwnership report (5% holder, passive, amended) | 03/26/2026 | None |
| 8-KDirector or officer change | 03/23/2026 | 03/17/2026 |
| S-8Registration of employee stock plan shares | 02/25/2026 | None |
| 10-KAnnual report | 02/25/2026 | 12/31/2025 |
| 8-KResults of operations | 02/25/2026 | 02/25/2026 |
67 insider ownership reports (Forms 3, 4, 5 and 144) were filed about Arcus Biosciences, Inc. in the last 12 months. They list trades by officers, directors and large holders; see them on SEC EDGAR.
Other pharmaceutical preparations
Swipe the table sideways to see more columns.
| Company | Headquarters | Revenue | Net income |
|---|---|---|---|
| Johnson & JohnsonJNJ | New Brunswick, NJ | $94.19B | $26.8B |
| Eli Lilly & CoLLY | Indianapolis, IN | $65.18B | $20.64B |
| Merck & Co., Inc.MRK | Rahway, NJ | $65.01B | $18.25B |
| Pfizer IncPFE | New York, NY | $62.58B | $7.77B |
| AbbVie Inc.ABBV | North Chicago, IL | $61.16B | $4.23B |
| Astrazeneca PLCAZN | Cambridge, United Kingdom | $58.74B | $10.22B |
| Bristol Myers Squibb CoBMY | Princeton, NJ | $48.19B | $7.05B |
| Abbott LaboratoriesABT | Abbott Park, IL | $44.33B | $6.52B |
Profile refreshed Oct 26, 2026; financials refreshed Oct 22, 2026.
Frequently asked questions
- What is Arcus Biosciences, Inc.'s CIK number?
- Arcus Biosciences, Inc.'s SEC Central Index Key (CIK) is 1724521.
- What is Arcus Biosciences, Inc.'s stock ticker?
- Arcus Biosciences, Inc. trades as NYSE: RCUS.
- What was Arcus Biosciences, Inc.'s revenue?
- Arcus Biosciences, Inc. reported revenue of $247M for the fiscal year ended Dec 31, 2025, -4.3% from the year before.
- When does Arcus Biosciences, Inc.'s fiscal year end?
- Arcus Biosciences, Inc.'s fiscal year end on file with the SEC is December 31; its most recent fiscal year ended Dec 31, 2025.
- Where is Arcus Biosciences, Inc. headquartered?
- Arcus Biosciences, Inc.'s principal executive office on file with the SEC is in Hayward, CA.
- Does Arcus Biosciences, Inc. sponsor H-1B visas?
- Department of Labor records show 8 certified H-1B filings and 0 certified PERM filings under the name Arcus Biosciences, Inc.
Source: U.S. Securities and Exchange Commission, EDGAR submissions and XBRL company facts · Last updated 10/26/2026